Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.Cmvv_fHs.js ...

Biomarin has a near $3bn per annum drug franchise, and is profitable. Elliott Investment Management may be attempting to ...

Many of us are on the lookout for simple swaps and lifestyle changes that can boost our health. One popular trend is using ...

The National Maternal and Child Health Care Center will begin neonatal screening for congenital hypothyroidism, ...

After hours: November 22 at 4:48 PM EST Loading Chart for AGIO ...

Perhaps first and foremost is the fact that some people are averse to its flavor. Meanwhile, a genetic condition called phenylketonuria makes the consumption of aspartame dangerous due to the presence ...

Current price $64.26 52-week high $99.56 ...

Meeder Asset Management Inc. grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 920.8 ...

a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter ...